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 23 
Abstract 24 
 25 
Primary effusion lymphoma (PEL) is a lymphogenic disorder associated with KSHV 26 
infection. Key to the survival and proliferation of PEL is the canonical NF-kB pathway 27 
that becomes constitutively activated following overexpression of the viral oncoprotein 28 
ks-vFLIP.  This arises from its capacity to form a complex with the modulatory subunit of 29 
the IKK kinase, IKK(or NEMO) resulting in the overproduction of proteins that promote 30 
cellular survival and prevent apoptosis; both of which are important drivers of 31 
tumourigenesis. Using a combination of cell based and biophysical assays together with 32 
structural techniques, we show that the observed resistance to cell death is largely 33 
independent of autophagy or major death receptor signalling pathways and 34 
demonstrate that direct targeting of the ks-vFLIP-IKKinteraction both in cells and in 35 
vitro can be achieved using IKK mimetic peptides. Our results further reveal that these 36 
peptides not only induce cell killing, but potently sensitise PEL to the pro-apoptotic 37 
agents tumour necrosis factor alpha and etoposide and are the first to confirm ks-vFLIP 38 
as a tractable target for the treatment of PEL and related disorders.  39 
 40 
 41 
 42 
 43 
 44 
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Importance 45 
 46 
KSHV vFLIP (ks-vFLIP) has been shown to have a crucial role in cellular transformation 47 
where it is vital for the survival and proliferation of primary effusion lymphoma (PEL), an 48 
aggressive malignancy associated with infection that is resistant to the majority of 49 
chemotherapeutic drugs. It operates via subversion of the canonical NF-B pathway that 50 
requires a physical interaction between ks-vFLIP and the IKK kinase modulatory subunit 51 
IKK. Whilst this interaction has been directly linked to protection against apoptosis, it is 52 
unclear whether the suppression of other cell death pathways implicated in ks-vFLIP 53 
pathogenesis are additional contributors. We demonstrate that the interaction between 54 
ks-vFLIP and IKKis pivotal in conferring resistance to apoptosis. Additionally, we show 55 
that the ks-vFLIP-IKKcomplex can be disrupted using peptides leading to direct killing 56 
and the sensitisation of PEL cells to pro-apoptotic agents. Our studies thus provide a 57 
framework for future therapeutic interventions. 58 
 59 
Introduction 60 
 61 
Kaposi’s sarcoma associated herpesvirus (KSHV) is the most common cause of 62 
malignancy amongst AIDS patients (1, 2). In addition to being the main etiological agent 63 
of Kaposi’s sarcoma (KS), KSHV infection has also been linked to primary effusion 64 
lymphoma (PEL) and multi-centric Castleman’s disease (3, 4). Whilst AIDS-KS can be 65 
successfully treated with anti-retroviral drugs at the early stages of onset, there are to 66 
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date no highly effective treatments for the advanced disease or associated 67 
lymphoproliferative disorders. In particular, PEL has an extremely poor prognosis for 68 
which average survival rates vary between 3-6 months following diagnosis, prompting 69 
an urgent need for the identification of novel drug targets and therapeutics. During the 70 
latent phase of infection, KSHV produces a limited number of viral proteins that are 71 
essential for subverting the host to promote survival, immune evasion, viral replication 72 
and propagation (5). One such protein is ks-vFLIP, a cellular FLIP homologue that targets 73 
the canonical and alternative NF-kB transcriptional pathways rendering them 74 
constitutively active (6, 7). This persistent activation results in the de-regulated 75 
overexpression of gene products known to promote cellular survival and inhibit 76 
apoptosis, both of which have been strongly implicated in transformation. It has also 77 
been demonstrated that ks-vFLIP is crucial for the proliferation of PEL (8, 9) promoting 78 
anchorage-independent survival of endothelial cells (10), whilst suppressing autophagy  79 
(11) and death receptor signalling (8, 12).  80 
 81 
Although persistent activation of both the canonical and alternative NF-kB pathways by 82 
KSHV have been documented, its effects on the canonical pathway have been the most 83 
extensively characterised.  Key to activation are the p65(RelA)/p50 or p65/c-Rel 84 
heterodimeric transcription factors (13-15). These are normally sequestered in the 85 
cytoplasm as a consequence of their associations with the IB family of inhibitory 86 
proteins that occlude their nuclear localisation sequences, thus preventing transit to the 87 
nucleus. On activation, the IB’s are targeted for degradation by the 26S proteosome 88 
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following phosphorylation and subsequent K48-linked ubiquitination. This culminates in 89 
the liberated transcription factors being able to enter the nucleus and initiate 90 
transcription of the various genes under their control. Central to this process is the IKK 91 
kinase complex or signalosome (16) that instigates the initial phosphorylation of the 92 
IB’s. The core IKK complex consists of the kinase subunits IKK and IKKtogether with 93 
the essential modulatory element IKK (also referred to as NEMO) that is the target for 94 
ks-vFLIP. By means of a physical interaction with IKK, ks-vFLIP is able to “lock” the IKK 95 
kinase complex into a persistently phosphorylated state via a mechanism that appears 96 
to be independent of known upstream cellular activators such as Traf2, Traf3, Traf6, 97 
LUBAC, Tak-1 and HOIL-1 (17) and is thus distinct to those resulting from stimulation by 98 
endogenous pro-inflammatory cytokines or cellular FLIP variants (18).   99 
 100 
In previous studies, the crystal structure of ks-vFLIP bound to IKK (PDB accession code 101 
3CL3) was determined (19). Pivotal to complex formation are amino acids within the 102 
230-248 region of IKK (a dimeric coiled-coil) that are accommodated within two clefts 103 
of a ks-vFLIP monomer. Significantly, disruption of important interacting residues within 104 
this sequence using site directed mutagenesis has been shown to drastically reduce the 105 
levels of NF-B activation. Here we report that a conformationally constrained, stapled 106 
peptide based on this interacting motif (spIKK) and an analogous GST-peptide fusion 107 
protein (GST- IKK) are not only competitive inhibitors of IKKboth in vitro, but when 108 
combined with etoposide (ETO) or tumour necrosis factor alpha (TNF, drastically 109 
reduce the viability of BC3 and BCP-1 cells. This is a direct consequence of removing the 110 
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apoptotic block imposed by the ks-vFLIP mediated overproduction of pro-survival/anti-111 
apoptotic proteins where there appears to be little co-involvement of ATG3 dependent 112 
autophagic and no involvement of important death receptor mediated pathways.  Our 113 
findings not only demonstrate ks-vFLIP as an amenable target for the treatment of PEL 114 
and other KSHV related malignancies using gene therapies, but also suggest that stapled 115 
peptides/helical mimetics could form a basis for the design of future high potency 116 
therapeutics.  117 
 118 
Materials and methods 119 
 120 
Cloning, Protein expression and Purification 121 
 122 
GB1 tagged ks-vFLIP 123 
 124 
ks-vFLIP (1-178) was PCR cloned into the EcoR1 and XhoI sites of GB1-pBR22b (a 125 
modified pET22b vector containing the Streptococcal protein G immunoglobulin domain 126 
fusion tag (GB1), kind gift from Paul Driscoll, Francis Crick Institute) using the primers  127 
GB1vFLIP-Fwd and GB1vFLIP-Rev (Table 1). The resulting plasmid, designed to generate 128 
a ks-vFLIP fusion protein with N and C-terminal GB1 and 6His tags respectively (GB1-ks-129 
vFLIP), was transformed into BL21(DE3) cells where single colonies were inoculated into 130 
LB media (supplemented with 100gml-1 ampicillin) and grown overnight at 37°C. These 131 
cultures were used to inoculate 2L flasks containing 800ml of 100gml-1 ampicillin 132 
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supplemented LB media and grown to an OD600=0.6-0.8. The flasks were subsequently 133 
induced with 1mM IPTG and the temperature reduced to 25°C overnight. The cultures 134 
were spun at 5,000g for 20 minutes and pellets stored at -80°C or alternatively, re-135 
suspended in lysis buffer (20mM Tris-HCl pH 8.5, 200mM NaCl, (BufferA) + 25mM 136 
Imidazole) and subjected to two rounds of lysis using a Vibra cell Sonicator. The 137 
resulting lysates were spun at 19,500g and supernatants passed through a 1.2 micron 138 
filter prior to loading onto a 5ml His-trap column pre-equilibrated in buffer A.  The 139 
column was washed with 20 column volumes of buffer A and GB1-ks-vFLIP eluted in 140 
buffer B (buffer A + 500mM Imidazole) using a 5CV step gradient. The resulting protein 141 
was then concentrated in a 10kDa cutoff vivaspinT concentrator and applied to a 142 
Superdex 26/60 S75 size exclusion column pre-equilibrated with Buffer A supplemented 143 
with 250mM Imidazole and 5mM DTT (or 0.3mM TCEP). The eluted fractions were 144 
analysed using SDS PAGE and those found to contain GB1-ks-vFLIP at a purity of >95% 145 
were pooled, concentrated to 100M using a 10kDa cutoff vivaspinT concentrator and 146 
stored at 4°C. Fractions used for crystallisation trials were dialysed into a buffer 147 
comprising 20mM Tris-HCl pH 8.5, 50mM glycine and 10mM TCEP-HCL prior to setup.  148 
 149 
IKK (150-272) and ks-vFLIP(1-178) 150 
 151 
Details for the production and purification of IKK(150-272) and ks-vFLIP(1-178) have 152 
been previously reported in Bagnéris et al, 2008 (19). 153 
 154 
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 155 
Expression of GST fusion peptides  156 
 157 
In order to express the IKKγ fusion peptides in Jurkat cells, a GST fusion protein was 158 
produced by first PCR amplifying the GST coding region of pGEX-4T1 using Phusion High 159 
Fidelity Polymerase (NEB), and the primers GST-Fwd and GST-Rev (Table 1). The PCR 160 
product was then cloned into a pJET-C1 vector (Fermentas). Following digestion of pJET-161 
C1-GST with BglII and SalI to release the GST coding sequence, the GST product was 162 
then cloned into the pDual-Cherry lentiviral vector (27) downstream of the SFFV 163 
promoter using the BglII/SalI sites. The resulting construct incorporated BamH1 and SalI 164 
sites at the C-terminus of GST that were used for insertion of the peptides. To produce 165 
the GST-IKK and GST-IKKDM constructs, IKK wild-type peptide primers (GST-IKK-Fwd 166 
and GST-IKK-Rev, Table 1) corresponding to the spIKK protein sequence (residues 230-167 
248 including a non-native C-terminal cysteine) or the same sequence modified to 168 
incorporate the F238R/D242R double mutant (GST-IKKDM-Fwd and GST-IKKDM-Rev) 169 
shown to drastically impair ks-vFLIP binding (28), were subsequently annealed at 95o C 170 
for 10 minutes before being ligated into the pDUAL-GST vector following digestion of 171 
the vector with BamH1 and SalI.  172 
 173 
Lentiviral vectors expressing GST or GST fusion peptides together with GFP, CherryFP, 174 
WT vFLIP or vFLIPA57L (a mutant which fails to bind IKK), were produced as previously 175 
described (19). These were used to transfect unmodified Jurkat cells, those lacking IKK 176 
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(20) and those in which ATG3 or FADD were down-regulated using a combination of two 177 
siRNAs for each mRNA (17) (target sequences provided in Table1), and also the human B 178 
cell line BC3 (a pleural effusion lymphoma (PEL) cell harbouring KSHV). In each case, 179 
lentiviral vector doses were used to ensure that over 95% of cells were positive for the 180 
relevant fluorescent protein. The anti-FADD antibody used for immunoblots was 181 
purchased from BD Biosciences with those for anti-ATG3 and anti-GAPDH from Cell 182 
Signalling Technology.  Jurkat cells and their IKK-null derivative were obtained from Dr 183 
Alain Israel, Institute Pasteur, and verified as human T cells by surface CD3 staining.  184 
BC3, BCP-1 and DG75 cells were purchased for this study from the ATCC (American Type 
Culture Collection), 
They were verified as human B cell lines by surface staining for human Ig.  185 
 186 
Cell viability assays 187 
 188 
The transfected cells, the human B cell lines BC3, BCP-1 or DG75 (a PEL cell line  189 
negative for KSHV and EBV) were treated with human TNF (PeproTech or Alomone 190 
Labs), ETO (Sigma), spIKKencompassing IKK residues 230-248, see Figure 3 for 191 
structure) or combinations of spIKKwith either TNFor ETO. Cell survival was 192 
determined after 24 and 48 hours by Trypan blue staining and counting with a 193 
haemocytometer.  Cell viability is expressed as a percentage of the number of viable 194 
cells per culture at the start of each experiment. Results show the mean and standard 195 
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deviation of triplicate independent experiments where the significance difference is 196 
calculated by two-way ANOVA with a Fisher’s LSD post test.  197 
 198 
Thermofluor assays 199 
 200 
Thermofluor studies were conducted using the MyIQ RT PCR system (BioRadT) in a 96 201 
well plate format. Trials were performed in which 30M ks-vFLIP (unless otherwise 202 
stated) was combined with either IKK or mimetic peptides (at the specified 203 
concentrations) prior to the addition of sypro-orange diluted in a 1:1000 (v/v) ratio and 204 
thermal denaturation. The data were subsequently processed using the BioRadT iQ5 205 
software. Each experiment was repeated at least 3 times. All peptides were purchased 206 
from Eurogentec. 207 
 208 
Crystallisation and structure determination of the GB1-ks-vFLIP-spIKK complex. 209 
 210 
spIKK(Eurogentec), was first dissolved in 100% DMSO to a concentration of 2mM. A 1:1 211 
ratio of GB1-ks-vFLIP to spIKK were next combined to give a final GB1-ks-vFLIP 212 
concentration of 50-70M. A MosquitoT crystallisation robot was used to set up vapour 213 
diffusion crystallisation trials involving a range of commercially available screens. 200nL 214 
drops (final volume) were dispensed in a 1:1 ratio of complex to well solution and after 215 
1 week, small crystals were observed in the condition 1.2M ammonium sulphate, 0.05M 216 
tri-sodium citrate and 3% isopropanol. In attempts to improve their size and diffraction 217 
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quality, the silver bulletT additive screen (Hampton Research) was used in conjunction 218 
with the above condition. Of the various additives, vitamin B12 produced the most 219 
significant improvements and was subsequently included in repeat trials of the original 220 
condition at a concentration of 0.1-0.2%.  221 
 222 
Crystals of the GB1-ks-vFLIP-spIKK complex, grown in the presence of vitamin B12, 223 
were cryo protected in 25-30% glycerol and flash frozen in liquid nitrogen prior to 224 
irradiation at SOLEIL on the Proxima 1 beamline. Data were collected to a maximum 225 
resolution of 3.3Å on two crystals that were integrated and scaled using XDS (21). The 226 
datasets were merged and truncated using AIMLESS (CCP4, (22, 23)) in space group P63. 227 
At this stage, the data were found to be significantly anisotropic which was 228 
subsequently corrected for using STARANISO (Global phasing, 229 
http://staraniso.globalphasing.org/cgi-bin/staraniso.cgi). The effective resolution of the 230 
corrected data was reduced to 3.38Å (giving an overall completeness of >95%, see Table 231 
2).  The structure was determined using molecular replacement in PHASER (24) where 232 
two GB1-ks-vFLIP monomers were identified in the asymmetric unit. Clear density for 233 
peptides associated with each monomer could be observed in the IKK binding sites that 234 
were subsequently modelled using COOT (25) along with those of the GB1 monomers 235 
which were comparatively poorly ordered. Although side chains could be identified for 236 
the majority of residues within each of the spIKK peptides, the aliphatic staples were 237 
only partially ordered. Refinement was performed using AUTOBUSTER (26) which 238 
incorporated NCS restraints together with TLS refinement, interspersed with manual re-239 
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building. Data collection statistics and those for the refined model can be found in Table 240 
2 and are within the expected ranges for a structure at this resolution. The co-ordinates 241 
have been deposited at the protein data bank under the accession code 5LDE. 242 
 243 
 244 
Isothermal calorimetry (ITC) 245 
 246 
ITC experiments were performed using a Microcal VP-ITCT micocalorimeter 247 
(MicroCal). For all binding reactions, syringe concentrations varied between ∼85 248 
and 100 μM for IKK(150-272), and cell concentrations between ∼8 and 10 μM for 249 
GB1-vFLIP. Titrations consisted of an initial 2 μl injection, followed by 20 10 μl 250 
injections with stirring at 300 rpm. In competition assays, GB1-ks-vFLIP was first 251 
incubated with 20M spIKK and DMSO to 4% prior to loading into the cell and 252 
titration with IKK(150-272). All ITC binding experiments were performed in de-253 
ionised water at 25°C owing to the buffer constraints of spIKK, GB1-ks-vFLIP and 254 
IKK(150-272) where GB1-ks-vFLIP and IKK(150-272) were buffer-matched by 255 
overnight dialysis, followed by the addition of 4% DMSO to each. It was 256 
confirmed that the use of de-ionised water and 4% DMSO had no discernable 257 
impact on structural integrity and/or the affinity of IKK(150-272) for GB1-ks-258 
vFLIP by parallel ITC experiments in which both proteins were alternatively 259 
dialysed into a buffer comprising 20mM Tris-HCl pH 8.5, 200mM NaCl and 0.3mM 260 
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TCEP. Comparable Kd’s to those obtained using de-ionised water were observed 261 
(see “spIKK is an effective mimetic of IKK” below and Figure 4). Following 262 
collection, all data were analyzed using the ORIGIN 70 software and fitted to a 263 
one-site binding model with each experiment performed at least in triplicate. 264 
 265 
Cell based immunoprecipitation assays 266 
 267 
To probe the ks-vFLIP-IKK interaction, Jurkat or BC3 cells were lysed and 268 
immunoprecipitation performed using an anti-IKK antibody (FL-419, Santa Cruz 269 
Biotechnology) or normal rabbit serum as a control. Lysates and immunoprecipitates 270 
were blotted using anti-ks-vFLIP antibodies (6). In vitro IKK kinase assays were 271 
performed as previously described (17).272 
 o
n
 O
ctober 12, 2017 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
  14 
Results 273 
 274 
The anti-apoptotic effects of ks-vFLIP overexpression are largely independent of 275 
autophagic and key death receptor signalling pathways. 276 
 277 
Although it has been established that dysregulated activation of the canonical NF-B 278 
pathway by ks-vFLIP renders mouse embryonic fibroblasts resistant to apoptosis 279 
induced by TNF(12), we sought to ascertain whether ks-vFLIP expression also prevents 280 
cell death induced by ETO. Unlike TNF that instigates death receptor signalling, ETO, a 281 
topoisomerase II inhibitor, initiates cell death through the generation of DNA double 282 
strand breaks (29). Our results revealed that at the highest concentration of ETO used 283 
(50M), the survival of Jurkat cells was only moderately reduced compared to those null 284 
for ks-vFLIP which were severely compromised (Figure 1A). The results with ETO closely 285 
mirror the trend observed for those treated with TNF (Figure 1B) and were consistent 286 
with those of Tolani et al (12), thus confirming ks-vFLIP as a key factor in the inhibition 287 
of apoptosis able to override the effects of both ETO and TNF. We next investigated 288 
the potential involvement of DISC formation and autophagy since ks-vFLIP has been 289 
cited (somewhat controversially) to interact with procaspase-8, an effector caspase 290 
whose activation requires the adaptor protein FADD (30) and to physically associate 291 
with the ubiquitin-like conjugating enzyme ATG3 that is essential for the formation of 292 
autophagosomes (11).  Viability assays were therefore conducted using Jurkat cells in 293 
which FADD and ATG3 were silenced (using siRNA) together with those null for IKK in 294 
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the presence of both ETO and TNF (Figures 1C and D). Figure 1E shows that the level of 295 
expression of ks-vFLIP in the engineered Jurkat cells is 3-5-fold greater than observed in 296 
the KSHV-transformed PEL cell line BC3 and that both FADD and ATG3 are undetectable 297 
by immunoblotting in those treated  with siRNA . Whilst cell survival was severely 298 
compromised in all three scenarios, it could to a large extent be rescued in the 299 
FADD/ATG3 siRNA Jurkat cells overexpressing WT ks-vFLIP, although to a lesser degree 300 
in the case of ATG3 and ETO. Only cells null for IKK were completely refractory to the 301 
protective effects of ks-vFLIP. Furthermore, the A57L ks-vFLIP mutant, that has been 302 
shown to disrupt IKKbinding (19), could not protect cells against apoptosis induced by 303 
ETO or TNF (Figures 1C and D) highlighting the importance of the ks-vFLIP-IKK 304 
interaction. 305 
 306 
Targeting the ks-vFLIP-IKK interaction and design of the IKK stapled peptide, spIKK  307 
 308 
Having ascertained that neither DISC formation or autophagy are major factors in 309 
conferring ks-vFLIP induced resistance to apoptosis we next investigated whether the 310 
ks-vFLIP-IKK interaction, shown to be essential, could be successfully disrupted by 311 
mimetic peptides in vitro. The original ks-vFLIP-IKK structure (3CL3) adopts a 312 
heterotetrameric configuration in which a ks-vFLIP dimer associates with IKKin a 313 
dimeric, parallel, helical coiled-coil conformation (Figure 2A). Although complex 314 
formation involves two distinct regions of ks-vFLIP (cleft 1 and cleft 2) simultaneously 315 
bound to each IKK monomer in the dimeric assembly (Figure 2A), it was shown that the 316 
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protein-protein interactions mediated by cleft 1 are crucial (19). We therefore sought to 317 
establish whether IKK binding to ks-vFLIP could be mimicked by single peptides 318 
incorporating residues shown to mediate important cleft 1 interactions. To achieve this, 319 
an unmodified 30mer peptide (residues 224-253) was designed to encompass the 320 
interacting motif and neighbouring residues along with a shorter 21mer (226-248), only 321 
marginally longer than the motif itself (230-248, Figure 2B). These were commercially 322 
synthesised and their ability to associate with ks-vFLIP assessed using a thermofluor 323 
assay (Figures 2C and D). Whilst neither the 21 or 30mer peptide could emulate the ~8°C 324 
shifts in melting temperature observed with the IKK(150-272) fragment used in the 325 
original structural studies at a concentration of 30M (contributions from denaturation 326 
of the IKK dimer being insignificant owing to its lack of a substantial hydrophobic core, 327 
Figure 2C), both gave rise to those of ~4°C at 100M despite being significantly different 328 
lengths. These results were the first indication that ks-vFLIP could be targeted using 329 
single peptides centred on the minimal interacting motif. 330 
 331 
The fact that we were able to at least partially substitute IKK for unmodified peptides, 332 
led us to investigate whether the IKK ks-vFLIP minimal interacting motif could be 333 
engineered into a conformationally constrained, helical peptide through incorporation 334 
of an appropriate aliphatic linker or “staple” (31). This strategy has been successfully 335 
used in several distinct systems involving protein-protein interactions mediated through 336 
helical recognition (32-35). It relies on the premise that one of the interacting partners 337 
can be simulated by a helical peptide resulting from the replacement of two non-338 
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essential amino acids by (S)-2-(2’ pentenyl) alanine that are subsequently cyclised to 339 
produce a constraining aliphatic linker. Such peptides have been frequently found to 340 
have enhanced affinity for their targets as well as innate cell permeability, thought to 341 
partially derive from the hydrophobic nature of the linker and favoured by an overall net 342 
positive charge. 343 
 344 
Inspection of the ks-vFLIP-IKK structure identified Q236 and E240 as potential sites on 345 
IKK for an i, i+4 staple given that they are non-essential (Figure 3A). To test our 346 
rationale in silico, a model peptide was constructed of the IKK minimal interacting 347 
motif (L230-S248) incorporating the staple and energy minimised (MMFF94x force field) 348 
using the MOE software package (Molecular Operating Environment (MOE), 2014.09; 349 
Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, 350 
Canada, H3A 2R7, 2015). Following minimisation, the helical geometry and overall 351 
configuration of the peptide were observed to remain unchanged. The model was then 352 
docked into cleft 1 of ks-vFLIP and the complex subjected to energy minimisation in 353 
which the position of the protein moiety was fixed whilst permitting movement of the 354 
peptide.  The resulting energy minimised complex revealed that all of the important 355 
interactions remained unperturbed. Based on these findings, the modified peptide 356 
(spIKK, Figure 3A) was subsequently synthesised with an added C-terminal cysteine to 357 
permit future conjugation to cell transporter molecules or fluorophores. Inclusion of this 358 
non-native residue had no effect on the protein-peptide interactions as initially judged 359 
by in silico modeling and later confirmed by in vitro studies (see below). 360 
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 361 
spIKK is an effective mimetic of IKK 362 
 363 
Our focus on a single peptide together with the presence of the aliphatic staple made it 364 
difficult to predict the exact nature of a ks-vFLIP-spIKK complex andin particular, its 365 
stoichiometry. To address this, we therefore co-crystallised ks-vFLIP with spIKK Similar 366 
to 3CL3, two molecules of GB1-ks-vFLIP were seen to comprise the asymmetric unit 367 
where further analysis revealed clear electron density for peptides bound to each ks-368 
vFLIP monomer (Figure 3B) Unexpectedly, sizeable density associated with the C-369 
terminal cysteines of the two peptides could also be identified. Based on size and overall 370 
shape, it is likely to originate from the vitamin B12 additive but owing to disorder, could 371 
not be unambiguously modelled for either monomer (Figure 3B). 372 
373 
The overall configuration of the ks-vFLIP-spIKK complex revealed a heterotetrameric 374 
arrangement analogous to that observed in 3CL3 where both peptides contacted clefts 1 375 
and 2 (Figure 3C). As indicated by our modelling studies, the ks-vFLIP-spIKK binding 376 
interface mediated by cleft 1 showed a high degree of structural similarity to the original 377 
ks-vFLIP-IKK(150-272) crystal structure. Crucially, the H235, F238, E242 and K246 378 
quartet central to binding and subsequent NF-kB activation, form similar contacts with 379 
the cleft 1 region in the peptide complex. Also in common with the ks-vFLIP-IKK(150-380 
272) heterotetramer, there were few specific interactions between spIKK and cleft 2 381 
(Figure 3C). Notably, however, the aliphatic staples replacing the side chain moieties of 382 
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Q236 and E240 (though only partially ordered)pack alongside the aromatic side chain of 383 
F53 located within the interface between cleft 1 and 2 where they form van Der Waals 384 
interactions. The high level of conservation between ks-vFLIP-spIKKand ks-vFLIP-385 
IKK(150-272) extends beyond the ks-vFLIP binding region to the peptide-peptide 386 
interface that adopts a very similar composition and configuration to the IKK dimer 387 
evident in 3CL3 (Figure 3C). This arises from the formation of a near identical non-388 
crystallographic dimer.  389 
 390 
We next sought to assess the affinity of spIKK for vFLIP using ITC. Owing to poor 391 
solubility in aqueous solutions, a competition assay was performed in which IKK was 392 
titrated into GB1-ks-vFLIP pre-incubated with spIKK(Figure 4A). In keeping with a high 393 
affinity, the apparent Kd of the vFLIP-IKK interaction in the presence of peptide 394 
increased approximately 80-fold from 380nM to 30M. This corresponds to a Ki of 395 
257nM and is thus comparable to that of IKK(150-272). 396 
 397 
GST-IKKand spIKK inhibit ks-vFLIP induced NF-B activation. 398 
 399 
Having established that peptides can mimic IKKon the basis of our thermofluor, 400 
structural and ITC studies, we next investigated their ability to attenuate NF-B 401 
activation. For cellular expression, a GST-IKK-20 mer fusion protein (comprising the 402 
exact amino acid sequence of spIKKincluding the non-native cysteine) was constructed, 403 
co-expressed with ks-vFLIP in Jurkat cells and probed for its capacity to disrupt assembly 404 
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of the ks-vFLIP-IKKcomplex (detected by immunoprecipitation using anti-IKK 405 
antibodies). Remarkably, the GST-peptide fusion protein virtually abolished formation of 406 
the ks-vFLIP-IKKcomplex (Figure 4B), demonstrating that peptides have the potential 407 
to severely attenuate NF-B activation in cells. The ability of spIKK to inhibit the ks-408 
vFLIP-IKK interaction in cell extracts was next assessed by treating Jurkat cell lysates 409 
with spIKK for one hour at 40C, followed by immunoprecipitation of IKK  and detection 410 
of any associated ks-vFLIP (Figure 4C). In parallel, IKK kinase activity in the 411 
immunoprecipitate (and hence NF-B activation) was also assessed by quantitatively 412 
measuring the levels of phosphorylation of added recombinant IB (Figure 4C)Our 413 
results revealed that the quantities of bound ks-vFLIP detected were substantially 414 
reduced in lysates treated with peptide. This trend was observed in the kinase assays 415 
which surprisingly showed that in the presence of spIKK, ks-vFLIP induced activation is 416 
reduced back to background levels. Similar results were also obtained when 417 
experiments were repeated with lysates from the PEL cell line BC3 in which ks-vFLIP is 418 
endogenously expressed (Figure 4D). Our findings demonstrate that spIKK can 419 
dissociate preformed ks-vFLIP-IKK complexes leading to the near abolition of induced 420 
NF-B activation.  421 
 422 
Both GST-IKKand spIKKpromote PEL cell killing, particularly in the presence of TNF 423 
and ETO. 424 
 425 
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Given their profound impact on NF-B activation, we next assessed whether 426 
IKKmimetic peptides could sensitise BC3 cells to TNF and ETO and thus stimulate cell 427 
death. To investigate this in cellulo, BC3 cells were transduced with the GST-428 
IKKpeptide vector prior to treatment with TNF or ETO and after 24 hours, their 429 
viabilities assessed.  As a control, similar trials were conducted but with GST-IKKDM 430 
that harbours the same peptide containing the F238R/D242R IKKdouble mutations 431 
previously shown to impair ks-vFLIP binding and consequently NF-B activation (28). The 432 
combination of GST-IKK and either TNFor ETO significantly reduced cell viability 433 
compared to GST-IKKDM and GST, (Figure 5A) consistent with removal of the ks-vFLIP 434 
induced apoptotic block. We also determined whether spIKKcould have a similar effect. 435 
Owing to the presence of the aliphatic linker and overall positive charge (+0.1), we 436 
reasoned that spIKKwas likely to be cell permeable based on studies involving a 437 
diverse range of unrelated stapled peptides (36-40). BC3 cells were therefore treated 438 
with spIKK either alone or in combination with TNF or ETO (Figure 5B) and their 439 
viabilities assessed after 24 hoursspIKK at the higher concentrations tested caused a 440 
significant reduction in their viability (IC50 ~75M after 24 hours). Either TNF or ETO 441 
caused a striking enhancement of spIKK-induced BC3 cell death (Figures 5B and C), but 442 
showed negligible effects individually. When viability was assessed at the later time of 443 
48 hours (Figure 5C), cultures treated with spIKK in the presence of either TNF or ETO 444 
remained free of viable cells, while in those treated with spIKK alone, viable cells 445 
remained. By contrast, similar experiments conducted in DG75 cells (a PEL cell line 446 
negative for both KSHV and EBV, Figure 5D), showed no change in sensitivity in the 447 
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presence of spIKKalone or when combined with either TNF or ETO. Considerable 448 
sensitivity to ETO, however, was detected after 48 hours (Figure 5E) consistent with its 449 
use as a therapeutic in the treatment of Burkitt’s lymphoma.  The effects of spIKK were 450 
further investigated on BCP-1 cells (an additional PEL cell line) where similar to BC3 451 
cultures, significant killing was observed for the peptide alone in contrast to ETO or 452 
TNF, with none remaining viable when used in combination with either agent  (Figure 453 
5F). 454 
  455 
 456 
Discussion 457 
 458 
The canonical NF-B pathway is an essential transcriptional mechanism that is hijacked 459 
by several viruses to prolong cellular survival and prevent apoptosis thus producing an 460 
environment conducive to viral propagation and ultimately proliferation. Although it has 461 
been established that ks-vFLIP is required for protection against apoptosis where it 462 
constitutively activates the pathway through physical association with IKK, it was 463 
unclear whether there might also be co-involvement of the DISC and/or autophagy. Our 464 
studies reveal that this protection is mostly independent of both, but interestingly 465 
demonstrates marked differences between the viabilities of ETO treated Jurkat cells 466 
expressing ks-vFLIP in the ATG3 and FADD knock downs and those treated with TNF. It 467 
has been reported that autophagy is a specific regulator of homologous recombination 468 
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(41) and since ETO functions by generating double strand breaks, may explain why 469 
rescue, though significant, is more limited in this background. Since ETO is currently in 470 
use for the treatment of B cell malignancies, our studies suggest avenues for future 471 
chemotherapeutic combinations. 472 
 473 
Although the canonical NF-B pathway itself is an obvious target for the treatment of 474 
PEL and other KS associated malignancies, its requirement in processes such as cellular 475 
differentiation, innate/adaptive immunity and developmental switching (42) make 476 
direct drug targeting likely to be associated with considerable toxicity. Given that ks-477 
vFLIP is virally encoded and significantly distinct from its cellular cFLIP homologues both 478 
structurally and functionally in terms of its mode of NF-B activation (18), inhibitors 479 
aimed at targeting its interaction with IKK are unlikely to have these effects.  Here we 480 
demonstrate that spIKK, a conformationally constrained 20mer helical peptide 481 
comprising the IKK interacting element, or an equivalent GST-peptide fusion protein 482 
(GST-IKK) can interact with ks-vFLIP and disrupt its association with IKK. Our crystal 483 
structure of ks-vFLIP bound to spIKKreveals that its mode of interaction directly mimics 484 
that of IKKin the original complex to the extent of forming a heterotetrameric ks-vFLIP-485 
spIKK assembly with conserved interactions in the spIKK-spIKK interface. A high 486 
affinity interaction is further illustrated by ITC studies which demonstrate that spIKK 487 
and IKK(150-272) have near equivalent binding affinities. We also show that 488 
spIKKand GST-IKK are potent attenuators of ks-vFLIP induced NF-B activation, 489 
illustrated by in vitro studies that include a kinase assay in which the levels of 490 
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phosphorylated IB following activation were assessed. Although the effects of vFLIP 491 
stimulation appear minimal, we find that the basal level of IKK activity in many 492 
transformed cell lines is high and that the extent of vFLIP stimulation is correspondingly 493 
small, though persistent (18). We have also found that more pronounced effects fail to 494 
be observed when assaying downstream events such as NF-kB transcriptional activity.  495 
Although spIKK is able to directly instigate BCP-1 and BC3 cell killing albeit at moderate 496 
concentrations (IC50 ~75M in BC3 cells, most likely as a consequence of sub-optimal 497 
permeability based on its comparable affinity to IKK,) both GST-IKK and spIKK 498 
sensitise PEL to ETO and TNFwhen ks-vFLIP is expressed.  499 
 500 
Whilst forming a useful tool compound, spIKK provides a template for the production 501 
of high affinity therapeutic peptides given that no attempts were made to optimise the 502 
sequence for maximal ks-vFLIP binding or cell permeability. Over the past decade, the 503 
use of conformationally constrained helical peptides to target previously intractable 504 
protein-protein interactions central to a diverse range of pathologies has grown 505 
substantially owing to the ease with which they can be produced, their inherent 506 
resistance to proteases and the fact that they are expected to be well tolerated given 507 
their more cognate nature (31, 43). In keeping with this, phase 1 clinical trials of a long 508 
acting growth hormone releasing hormone agonist peptide for the potential treatment 509 
of metabolic/endocrine diseases as well as HIV have so far been successful. In addition 510 
to drug-based therapeutics, our studies further illustrate that it is possible to mimic IKK 511 
 o
n
 O
ctober 12, 2017 by SW
ETS SUBSCRIPTIO
N SERVICE
http://jvi.asm.org/
D
ow
nloaded from
 
  25 
using a GST-peptide fusion protein and thus provide an alternative platform for the 512 
specific development of PEL or KS directed gene therapies.  513 
514 
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Figure Legends 655 
 656 
Figure 1. The anti-apoptotic effects of ks-vFLIP overexpression in Jurkat cells. Viability 657 
assays conducted in Jurkat cells treated with varying concentrations of (A) ETO and (B) 658 
TNF. The ability of ks-vFLIP to protect Jurkat cells against the effects of (C) ETO and (D) 659 
TNFwhere FADD and ATG3 have been silenced using siRNA, together with those null 660 
for IKK. (E). Left hand panel. Immunoblot comparing ks-vFLIP levels in Jurkat vFLIP cells 661 
with those in the KSHV-transformed PEL cell line BC3. Right hand panels. Down-662 
regulation of FADD and ATG3 in Jurkat cells using siRNA.  663 
 664 
Figure2. The vFLIP-IKK interaction and peptide thermofluor analysis (A). Right: Cartoon 665 
depiction of the ks-vFLIP-IKK heterotetramic complex (PDB accession code 3CL3). The 666 
IKK and ks-vFLIP monomers are shown in grey and wheat respectively. Left: The ks-667 
vFLIP-IKKdimer interface highlighting cleft 1 (white) and cleft 2 (greencyan). Residues 668 
essential for the formation of the cleft 1 interactions (H235, F238, D242 and K246) are 669 
coloured magenta and those that interact with cleft2 (Q236 and E240), blue. (B) The 670 
IKK ks-vFLIP minimal interacting motif (residues 230-248) together with those forming 671 
the 30 and 21mer peptides (pink and violet respectively) used in the thermofluor studies. 672 
(C). Thermal denaturation profiles for (Left) ks-vFLIP and (Right) IKK at varying 673 
concentrations. The lack of a significant response over the range of concentrations 674 
tested for IKK is owing to its dimeric coiled-configuration that lacks a substantial 675 
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hydrophobic core. (D). The thermal denaturation of ks-vFLIP in the presence of varying 676 
concentrations of (left) IKKand (right) the 21 (pink) and 30 mer (violet) peptides.   677 
 678 
Figure 3. spIKK and the crystal structure of the GB1-ks-vFLIP-spIKK complex. (A) 679 
(Left). The in-silico designed IKK mimetic peptide (spIKK sequence, together with the 680 
position and structure of (S)-2-(2’ pentenyl) alanine used to replace Q236 and E240 681 
(green). The key cleft 1 binding residues are depicted in magenta. Right. The energy 682 
minimised model of spIKKhighlighting the aliphatic linker (green) after cyclisation and 683 
its position relative to the cleft 1 binding residues on the opposite face of the helix. 684 
 (B). (Left). The refined co-ordinates of spIKKsuperimposed on the initial 2mFo-DFc 685 
electron density map (blue, contoured at 1) calculated using the co-ordinates of ks-686 
vFLIP from 3CL3.pdb alone after molecular replacement. (Right). The 2mFo-DFc (blue, 687 
contoured at 1and mFo-DFc (green, contoured at 3electron densities associated 688 
with the C-terminal cysteine of one spIKKpeptide (C). (Left). The ks-vFLIP-spIKKdimer 689 
interface (for the purposes of clarity, one IKK monomer is depicted as a cartoon (light 690 
grey)). The cleft 1 interactions (magenta for spIKK and yellow orange for cleft 1 in ks-691 
vFLIP) are entirely conserved. The aliphatic staple (green), though partially ordered, 692 
projects into the cavity between cleft 1 and cleft 2 (greencyan) of the opposite ks-vFLIP 693 
monomer alongside F53. (Right). The spIKK-spIKK dimer (grey) superimposed on the 694 
analogous interface in 3CL3.pdb (pink) shows an almost identical configuration and 695 
arrangement of residues.  696 
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Figure 4. ITC experiments and the effects of IKK mimetic peptides on NF-B activation. 697 
(A) (Top). ITC data obtained for: (Left), IKK titrated into GB1-ks-vFLIP in which both 698 
proteins were dialysed into de-ionised water, (Middle), the analogous experiment but 699 
with the proteins dialysed into buffer (see materials and methods) and (Right) a 700 
competition assay in which spIKK was incubated with GB1-ks-vFLIP prior to titration of 701 
IKK(performed in de-ionised water). (Bottom). Table showing the corresponding 702 
“apparent” Kd’s and Ki for spIKK.  (B) Immunoprecipitation assays involving Jurkat cell 703 
lysates where ks-vFLIP was expressed in the presence and absence of GST-IKK using 704 
anti-IKKantiserum (upper panel) and normal rabbit serum (lower panel). GST-IKK 705 
prevents the association of ks-vFLIP with IKKevidenced by the absence of ks-vFLIP from 706 
the pellet fraction. (C). (Top). Immunoprecipitation trials using Jurkat cell lysates treated 707 
with 50M spIKK in which ks-vFLIP was absent or overexpressed. (Bottom). The results 708 
of a kinase assay measuring the levels of phosphorylated IB in the presence and 709 
absence of spIKK. (D). Similar to (C) but where immunopreciptation assays were 710 
performed using BC3 cell lysates. The rabbit anti-serum control is shown in the left 711 
panel. 712 
 713 
Figure 5. The capacity of IKK mimetic peptides to kill BC3 and BCP-1 cells in the 714 
presence/absence of TNF and ETO. (A) Viability assays using BC3 cells co-expressing 715 
GST-IKK (or GST-IKKDM harbouring the F238A/D242R double mutant known to impair 716 
both vFLIP binding and NF-kB activation) and ks-vFLIP alone or following treatment with 717 
TNF or ETO. (B). Viability assays in which BC3 cells expressing ks-vFLIP were treated 718 
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with varying concentrations of spIKKin the presence and absence of TNF or ETO at 719 
the specified concentrations. (C). Assays in which the viability of BC3 cells treated with 720 
spIKK, TNFETO or combinations of spIKKand TNF or ETO (at the specified 721 
concentrations) were monitored after 24 and 48 hours. The curves for spIKK+ TNF 722 
(magenta) and spIKK+ ETO (yellow) are overlapping. (D) The effects of TNF and ETO 723 
(at the specified concentrations) on the viability of DG75 cells at varying concentrations 724 
of spIKK (E) Control experiment illustrating the individual effects of spIKK, TNF and 725 
ETO together with the spIKKTNF and spIKKETO combinations on the viability of 726 
DG75 cells (at the specified concentrations) at 24 and 48 hours. Whilst spIKK and TNF 727 
fail to have a negative impact (either alone or in combination), a significant reduction in 728 
viability is observed for those treated with ETO (or ETO + spIKK at 48 hours.  (F) 729 
Viability assays conducted in BCP-1 cells similar to those in (A), but performed at the 730 
indicated concentrations of spIKK TNF and ETO. 731 
 732 
733 
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Tables 734 
 735 
Table 1: List of all primers used to produce the various plasmid constructs detailed 736 
together with target sequences for the FADD and Atg3 siRNA’s. The restriction sites, 737 
stop codons and those mutated in the IKK double mutant GST constructs (GST-IKKDM-738 
Fwd  and GST-IKKDM-Rev ) have been underlined. 739 
 740 
 741 
 742 
 743 
 744 
 745 
 746 
 747 
 748 
  749 
Primer   
  
GB1vFLIP-Fwd ttgaattcgatggccacttacg 
GB1vFLIP-Rev aactcgagcgcctatggtg 
  
GST Fwd agatctGCCACCATGTCCCCTATACTAGGTTATTGG 
GST Rev gtcgacctactactaggatccACGCGGAACCAGACCACCACC 
  
GST-IKK-Fwd gatccTTGCAGGTGGCCTATCACCAGCTCTTCCAAGAATACGACAACC
ACATCAAGAGCAGCGTGGTGGGCAGTtag 
GST-IKK-Rev tcgactaACTGCCCACCACGCTGCTCTTGATGTGGTTGTCGTATTCTT
GGAAGAGCTGGTGATAGGCCACCTGCAAg 
GST-IKKDM-Fwd gatccTTGCAGGTGGCCTATCACCAGCTCcgCCAAGAATACcgCAACC
ACATCAAGAGCAGCGTGGTGGGCAGTtag 
GST-IKKDM-Rev 
 
FADD target 1  
FADD target 2  
ATG3 target 1  
ATG3 target 2 
tcgactaACTGCCCACCACGCTGCTCTTGATGTGGTTGcgGTATTCTT
GGcgGAGCTGGTGATAGGCCACCTGCAAg 
 
CATGGAACTCAGACGCATCTA 
TGAACTCAAGCTGCGTTTATT 
CCAGAACTTATGACCTTTACA  
ATGTGACCATTGACCATATTT 
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Table 2. Data collection, processing and refinement statistics. 750 
Space group P63 
Unit cell [a, b, c (Å)] a=b=90.48, c=134.75 
==90, =120 
Resolution (Å) 78.5–3.3 (3.3–3.6) 
Total no. of reflections 89313 
No. of unique reflections 9482 
Redundancy 9.4 (9.6) 
Completeness (%) 99.80 (99.7) 
<I>/<σ(I)> 10.3 (1.3) 
Rmeas
a 0.11 (1.8) 
Refinement (Staraniso corrected data)   
                  Resolution (Å) 25-3.4 (3.4-3.8) 
    No. of protein/peptide atoms 3437 
                  Completeness (%) 95.7 (85.2) 
    Rworkb/Rfreec (%) 25.7/29.0 
    Estimated co-ordinate error based on Rfree (Å) 0.61 
    Mean B-factor (Å2) 135 
Deviations from ideal stereochemistry  
    RMSD bonds (Å) 0.009 
    RMSD angles (°) 1.03 
    Wilson B-factor (Å2) 115 
Ramachandran plot analysisd  
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    Most favoured (%) 95.6 
    Additionally allowed (%) 2.64 
    Disallowed (%) 1.76 
  
 751 
Values in parentheses are for the highest resolution shell (3.4–3.8 Å). 752 
aRmeas=Σ((N/N-1))
1/2(|Ii – <I>|)/Σ(<I>)], where the sum is calculated over all observations 753 
of a measured reflection (Ii), <I> is the mean intensity of all the measured observations 754 
(Ii), and N the total number of observations for each reflection. 755 
bRwork=Σ (|Fobs – Fcalc|)/Σ (Fobs), Fobs are the observed structure factor amplitudes, and Fcalc 756 
those calculated from the model.  757 
cRfree is equivalent to Rwork but where 5% of the measured reflections have been 758 
excluded from refinement and set aside for cross-validation purposes. 759 
dRamachandran plot analysis was from molprobity 760 
(http://molprobity.biochem.duke.edu/). 761 
 762 
 763 
  764 
 765 
 766 
 767 
 768 
 769 
 770 
 771 
 772 
 773 
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 774 
 775 
 776 
                               777 
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